Stay updated with breaking news from Travis Mickle. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted the Orphan Drug Designation to serdexmethylphenidate, KemPharm’s proprietary prodrug of d-methylphenidate for the treatment of idiopathic hypersomnia
The FDA has granted Orphan Drug designation to serdexmethylphenidate (KP1077) for the treatment of idiopathic hypersomnia.
KemPharm has received the Orphan Drug Designation from the US FDA for serdexmethylphenidate to treat idiopathic hypersomnia.
The FDA has granted Orphan Drug designation to serdexmethylphenidate (KP1077) for the treatment of idiopathic hypersomnia.
18.11.2022 - Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov. 18, 2022 (GLOBE NEWSWIRE) - KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a biotechnology company ... Seite 1